May This Year Bring New Happiness, New Goals, New Achievements, And A Lot Of New Inspirations On Your Life. Wishing You A Year Fully Loaded With Happiness.
Call Now For Subscriptions ☎ +91 9980555517 ๐ฑ +91 9900017008
Thursday, December 31, 2020
Friday, December 25, 2020
Merry Christmas 2020
Wishing You And Your Family Health,
Happiness, Peace & Prosperity
This Holiday Season.
Thursday, December 24, 2020
Please Rollover Nickel Short Positions In January 2021 Series...
Given To All Of You As A Free Live Trades On 14th October 2020
MCX Nickel December
2 Lots Short Sell Given 1136
Now Cmp: 1290
Please Rollover Now In January 2021 Series
Now Cmp: 1266
Now Our Costing For 2 Lots Nickel Is Now 1112
HOLD WITHOUT STOPLOSS FOR HUGE RETURN ONLY
SO FOR TIME BEING POSITION OPEN WITHOUT STOPLOSS
Pay Now & Join Super Signature HNI Positional Profit Plan, Call
09980555517
Friday, December 18, 2020
Please Book MCX CrudeOil At 3603 & Also Rollover The Positions In January 2021
MCX CrudeOil December
BOOK INFY NOW AT 1194
Given To You As A Free Live Trade On The Date Of 23rd Oct 2020, Check here:
https://twitter.com/arbindtiwariT/status/1319519053216559105
Also Given Here On My Blog Also
Friday, December 11, 2020
BHEL Next Move
BHEL’s scope of work in the contract includes design, supply, testing, installation & commissioning along with a comprehensive five-year AMC of the systems at three different locations. The project will be executed by BHEL’s Electronics Division, Bengaluru. BHEL has a focused approach in the emerging field of BESS and has already commissioned a 1 MWh BESS at its Corporate R&D Centre located in Hyderabad. The state-of-the-art system is commissioned with three different battery technologies viz. Lithium-Ion, Advance Lead-Carbon and Flow batteries.
Long-term investors can reap rewards.
BUY RECOMMENDATION FROM ARBIND TIWARI FOR TARGET 75/90
Friday, December 4, 2020
Book Now TATASTEEL At 625
#TataSteel
Book ExideInd At 186
#exide #ExideInd
Book Sunpharma Now At 555
#SunPharma
Tuesday, November 24, 2020
Open Positions On Blog
#INFY Future December
#MCX CrudeOil December
#MCX Nickel December
Hold Only For Huge Return..
Pay Now & Join Super Signature HNI Positional Profit Plan, Call
09980555517
Ask Bank Details For Subscriptions If You Have Rs. 50 Lac+++
09900017008
Rollover Positions In December Series Now.. INFY Future
Given To All As A Live Free Trades>>>>>
Please Rollover In December Series Now On Immediate Basis
Saturday, November 21, 2020
Minimum Return / Stocks More Then 25%
After Filter Got #Six Stocks Futures 4 U
Now I Can Expect Big Moves In That 6 Stocks Minimum Return / Stocks More Then 25% 5 Lots Each 30 Lots Total Holding.. Minimum Required Capital: Rs. 70 Lac Total Quantity: 55255 Risk Rs. 20 Lac Return Rs. 1.50 Crore Accuracy 100%Friday, November 20, 2020
My Personal View For TATASTEEL
TATASTEEL
LTP: 533
Expected Upside: 675
Its My Personal View For This Target 675. Buy Recommendations For All The Investors or Traders. Medium Term To Long Term Prospective. All the Fundamentals & Technical Levels Also Providing Indications For Strong Buy.
For More Details, Call Me
+91 9980555517
Whats App Me
+91 9900017008
My View On ExideInd
Exide Industries
LTP: 171.50
Expected Upside: 205
"Exide Industries reported better than expected results as sales/EBITDA/net profit were higher than our forecasts by 11/19/27 percent. We raise FY21 sales/EBITDA/EPS estimates by 6/11/14 percent respectively given better than expected Q2FY21 results. We also raise FY22 estimates by 4/7/9 percent. Our SOTP based target price (based on FY23 earnings) stands at Rs 205". Its My personal view and 100% buy recommendations for all traders or investors. I believe to hold positions from short term to long term. This target is for very short term to mid term period.
For More Details, Call Me
+91 9980555517
Whats App Me
+91 9900017008
My View On A Pharmaceutical Stock That Not Moved Still But Very Soon ๐๐๐๐๐๐๐๐๐๐๐งจ๐๐๐
Sun Pharmaceutical Industries
LTP: Rs 503.80
Target price: Rs 618
Expected Upside More Then Written Price
The brokerage believes the US business for Sun Pharma (excluding Taro Pharmaceuticals and Dusa Pharmaceuticals) should start growing as 92 ANDAs (abbreviated new drug applications) and 6 NDAs, which are pending approval, gradually start reflecting in incremental revenues.
Price erosion in base business is unlikely to be painful as the same is now commoditised with a median competitive intensity of eight players across its marketed ANDA portfolio.
In addition to complex ANDAs, Sun Pharma is also aggressively developing value-added generic drugs that are targeting the following segments:
1) Patients suffering from dysphagia.
2) Dosing convenience.
3) Improved health care administration.
The domestic business should deliver a low double-digit growth and outpace the Indian pharmaceutical market driven by its large exposure to the chronic segment. the brokerage said.
For More Details, Call Me
+91 9980555517
Whats App Me
+91 9900017008
#Nifty Spot Is Trading Near 23,400 For Time Being Last Hope For Fast Recovery.. For Time being Last Hope For #Bulls 22,850-22,900 On...
-
#Index Update.... #Nifty Spot In Trading Around 24,235 Almost Down 248 Points ( 1.01%) #NiftyBank Spot Is Trading Around 51,980 Almost ...
-
RBI’s MPC will announce its interest rate decision on Oct 1. What can India expect from the policy? #RBI #MPC #RBIMPCPolicy #NavratriUt...
-
100% All Rollover Completed Now.. Hold All Your Positions In October & Above Series.. #Nifty Spot Trading Near 24,675 #NiftyBank Spo...


